ReviewClinical ophthalmology (Auckland, N.Z.)2014
Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.
Review in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 58 citations in OpenAlex.
- Sex Differences in the Lacrimal Gland: Implications for Dry Eye Disease.International journal of molecular sciences · 2025Review
- Overview of Dry Eye Disease for Primary Care Physicians.Medicina (Kaunas, Lithuania) · 2025Review
- Inflammation mechanism and anti-inflammatory therapy of dry eye.Frontiers in medicine · 2024Review
- Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2023Review
- Regulation of Axon Guidance by Slit2 and Netrin-1 Signaling in the Lacrimal Gland of Aqp5 Knockout Mice.Investigative ophthalmology & visual science · 2023Article
- Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease.Diseases (Basel, Switzerland) · 2023Review
- Intricate insights into immune response in dry eye disease.Indian journal of ophthalmology · 2023Review
- Dry eye syndrome: comprehensive etiologies and recent clinical trials.International ophthalmology · 2022Review
- A Practical Approach to Severity Classification and Treatment of Dry Eye Disease: A Proposal from the Mexican Dry Eye Disease Expert Panel.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Experimental Models, Induction Protocols, and Measured Parameters in Dry Eye Disease: Focusing on Practical Implications for Experimental Research.International journal of molecular sciences · 2021Review
- Protective effects of low-molecular-weight components of adipose stem cell-derived conditioned medium on dry eye syndrome in mice.Scientific reports · 2021Article
- Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine.Frontiers in medicine · 2021Review
- Outcomes of Sjögren's versus non-Sjögren's related dry eye in a longitudinal, tertiary clinic-based sample.PloS one · 2021Observational
- Autoimmune Dry Eye without Significant Ocular Surface Co-Morbidities and Mental Health.Vision (Basel, Switzerland) · 2020Review
- Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases.Pharmaceutics · 2020Review
- Article
- Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits.Journal of clinical medicine · 2019Review
- Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis.The ocular surface · 2018Article
- Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease.Translational vision science & technology · 2018Article
- Alteration in nerves and neurotransmitter stimulation of lacrimal gland secretion in the TSP-1Mucosal immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye from Sjögren's syndrome is a multifactorial disease that results in dysfunction of the lacrimal functional unit. Studies have shown changes in tear composition, including inflammatory cytokines, chemokines, and metalloproteinase. T-lymphocytes have been shown to increase in the conjunctiva and lacrimal glands in patient and animal models. This inflammation is in part responsible for the pathogenesis of the disease, which results in symptoms of eye irritation, ocular surface epithelial disease, and loss of corneal barrier function. There are a number of anti-inflammatory approaches for treating this disease. The current study reviews details of immune response and anti-inflammatory therapies used to control this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.